A comparison of the safety and efficacy of tapinarof and roflumilast topical therapies in the management of mild-to-moderate plaque psoriasis
Skin Res Technol. 2024 Sep;30:e70041 doi: 10.1111/srt.70041
Ghani et al. compared the efficacy and safety profiles of tapinarof and roflumilast for treating mild-to-moderate plaque psoriasis. Both therapies showed robust efficacy and were well-tolerated, with low rates of adverse events. Tapinarof exhibited marginally higher efficacy in PASI scores compared to roflumilast.
The study utilised a literature review to identify four studies for tapinarof and five for roflumilast, assessing their therapeutic roles and safety in psoriasis management. The aim was to establish the clinical viability of these emerging topical agents in comparison to conventional treatments.
